A diagnosis of idiopathic thrombocytopenic purpura (ITP) was made. She was placed on oral prednisolone 75 mg/day and her Plt count increased to 360 × 10 3 /m 3 by the end of second week. In the fourth week when she received 50 mg/day of prednisolone, Plt count dropped to 80 × 10 3 /m 3 .
Over the next 2 months, because she had some adverse effects of the corticosteroid (dyspepsia and generalized edema), prednisolone was tapered to 7.5 mg every other day and danazol 400 mg/day was begun. The Plt count was between 40 × 10 3 and 80 × 10 3 /m 3 and she was symptom-free.
In the sixth month, again she experienced spontaneous mucosal bleeding and the Plt count dropped to 8 × 10 3 /m 3 . She was admitted to the hospital and received hydrocortisone 400 mg/day and high-dose intravenous immunoglobulin (IVIG) 400 mg/kg for 5 days, which gave a transient increase in Plt count that dropped again after 2 weeks.
She underwent splenectomy and its pathology revealed reactive hyperplastic change. On the second day after surgery her Plt count was 86 × 10 3 /m 3 but dropped to less than 10 × 10 3 /m 3 on the fourth day. She was placed on high-dose methylprednisolone 1500 mg/day that gave no response. After 2 weeks her Plt count was less than 10 × 10 3 /m 3 and she had a bloody secretion in her drain bag. She received two courses of vincristin 1 mg/week with no increase in Plt count.
A bone marrow biopsy was repeated and specimens reviewed by an expert hematologist were compatible with ITP and there was no myelodysplastic or neoplastic change.
After about 9 months of treatment the patient was refractory to medications, Plt count was less than 50 × 10 3 /m 3 , and her mucosa surfaces had easy bruising ( Fig. 1 ). Finally we decided to place the patient on anti-CD20 monoclonal antibody, rituximab. She received the drug in four weekly doses of 375 mg/m 2 and her Plt count increased to 188 × 10 3 /m 3 ) in 2 months. About 18 months after treatment the patient has no complaint, does not have a Plt count of less than 80 × 10 3 /m 3 , and her Plt count has increased gradually.
DISCUSSION
ITP is an immune-mediated disorder characterized by accelerated and premature destruction of platelets by the reticuloendothelial system (1). Spontaneous remission is rare in adult patients but about 50% of cases respond to primary treatments including corticosteroid, IVIG, anti-RhD immunoglobulin, and splenectomy (2) .
Chronic and refractory patients who fail primary modalities and experience sustained thrombocytopenia are difficult to manage. Treatments that aim at suppressing the production of autoantibodies and inhibiting macrophage-mediated destruction of opsonized platelets include danazol, cytotoxic/immunosuppressive chemotherapy agents (cyclophosphamide, vincristine, azathioprine), and the new anti-CD20 monoclonal antibody (2,3). CD20, a transmembrane B-cell-specific antigen, is a potential target for treatment of certain malignant and nonmalignant plasma cell disorders (4) . Rituximab is a genetically engineered human anti-CD20 monoclonal antibody that is approved for the treatment of low-grade non-Hodgkin's lymphoma. Recent clinical reports suggest that rituximab may be useful in treating certain patients with chronic refractory ITP (3) (4) (5) (6) (7) (8) (9) (10) .
Possible mechanisms for rituximab's activity are the destruction of autoantibody-producing plasma cells and the blockade of immune effector cell-mediated destruction of antibody-coated platelets (4).
Perotta et al (10) have reported a series of 10 patients with chronic ITP who failed to respond initial treatments and 9 of whom had undergone splenectomy. Patients received rituximab 375 mg/m 2 weekly for 4 weeks. Five patients (50%) had a complete response (CR) (Plt count > 100 × 10 3 /m 3 ) and one (10%) had a partial response (PR) (Plt count 50-100 × 10 3 /m 3 ) and the duration of response was between 1 and 14 months.
Saleh et al (3) conducted a phase I/II clinical trial of 13 patients with refractory ITP. Rituximab was well tolerated with no obvious toxicity. PR was detected in two patients and lasted for 3 to 6 months and only one patient showed a CR for more than 6 months and all received full doses. Stasi et al (6) reported a cohort of 25 chronic ITP patients. In their study they found 5 patients with CR, 5 patients with PR, and 3 patients with a minor response (MR) (Plt count < 50 × 10 3 /m 3 , with no need for continuous treatment) and overall response was 52%, which lasted for at least 6 months. There are also some anecdotal case reports of chronic ITP patients treated with rituximab that show promising results.
In the current reported case, as shown in Fig.  1 , the patient was refractory to all medications after about 1 year of treatment, but when she received rituximab she experienced a CR for more than 18 months, with minimal side effects of the treatment. In the follow-up period, in the seventh month, her Plt count declined to less than 100 × 10 3 /m 3 , and there has been no need for any additional course of treatment.
In conclusion, we have no clear guidelines for management of chronic refractory ITP. Rituximab, as an anti-CD20 monoclonal antibody, shows some application in this field, but proper use of this treatment, alone and in combination with other modalities, needs further study.
